Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With Chemotherapy and Radiotherapy in First-line ES-SCLC
NCT07425795Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in small cell lung cancer (SCLC), sponsored by Chongqing University Cancer Hospital. Started Oct 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07425795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425795.